Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (October 12th Preview)
-
Bristol Myers Squibb pipeline: Phase 3 momentum for fibrosis and RayzeBio
Bristol Myers Squibb reported a pair of Phase 3 wins tied to its fibrosis and RayzeBio programs, underscoring renewed clinical momentum for the company’s oncology and organ-disease pipeline. The company’s Monday update followed an earlier readout in which one of its lung fibrosis efforts, admilparant, fell short of a main objective. The Phase 3 successes also highlight BMS’s continued effort to diversify late-stage risk across multiple modalities—an approach that matters as investors weigh probability-of-success across a crowded late-stage landscape.
-
FDA and regulatory approvals: Herpes drug cleared after acquisition
Asahi Kasei’s Hovilpri (approved for treating lesions caused by herpes simplex virus) received FDA approval, validating a key milestone following the company’s $919 million acquisition of AiCuris Anti-Infective Cures. The once-daily pill adds another market-ready antiviral option as clinicians manage HSV-related morbidity and recurrence risk. The approval also reflects how acquirers are monetizing late-stage assets post-deal, a pressure point for business development teams navigating timelines and regulatory execution.
-
Cancer immunotherapy endurance: KEYNOTE-966 3-year durability in biliary tract cancer
Three-year follow-up from the Phase 3 KEYNOTE-966 trial confirms that adding pembrolizumab to gemcitabine plus cisplatin maintains a durable overall survival benefit in advanced biliary tract cancer, with no new safety signals reported. The update strengthens the evidence base for continued first-line checkpoint inhibitor use alongside chemotherapy. For oncology teams, the longer-duration dataset narrows the gap between earlier readouts and durability questions that often shape uptake decisions and guideline positioning.
-
Turnaround in super-early diagnostics: Urine test gets FDA clearance for invasive aspergillosis
Johns Hopkins Medicine researchers provided clinical validation supporting the first FDA-cleared rapid urine test to aid diagnosis of invasive aspergillosis. The clearance moves fungal diagnostics closer to more scalable bedside workflows, where faster identification can affect antifungal initiation timing. If adopted broadly, urine-based triage could reduce reliance on slower laboratory pathways, particularly in high-risk patients where diagnostic uncertainty can delay effective therapy.
-
Telemedicine impact: virtual urgent care keeps most patients out of ED
A consultant-led virtual urgent care clinic at Cork University Hospital managed 73.1% of 2,584 referred patients without any emergency department attendance during its first six months, with no adverse events reported. The real-world utilization results add evidence that structured virtual triage can safely absorb a meaningful share of urgent-care demand. For healthcare systems under cost and capacity pressure, the study supports operational models that shift lower-acuity cases away from ED settings—an outcome that can influence adoption of digital care pathways.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.